Literature DB >> 21921047

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Sherine F Elsawa1, Anne J Novak, Steven C Ziesmer, Luciana L Almada, Lucy S Hodge, Deanna M Grote, Thomas E Witzig, Martin E Fernandez-Zapico, Stephen M Ansell.   

Abstract

Although proinflammatory and chemotactic cytokines can profoundly affect the tumor microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical models, the role of these molecules in Waldenström macroglobulinemia (WM) remains poorly understood. In this study, simultaneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM patients whereas IL-8 and EGF levels were significantly lower in these patients compared with healthy controls. Interestingly, CCL5 levels positively correlated with features of disease aggressiveness such as elevated IgM levels and bone marrow involvement. Functional analysis of tumor microenvironment revealed a functional correlation between CCL5 levels and IL-6 levels, a proinflammatory cytokine with an important role in normal and malignant B-cell biology. Furthermore, CCL5 stimulated IL-6 secretion in WM stromal cells resulting in increased IgM secretion by WM malignant cells via the JAK/STAT signaling pathway. Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921047      PMCID: PMC3217355          DOI: 10.1182/blood-2011-04-351742

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Cell-specific differences in the regulation of IL-6 expression by PMA.

Authors:  C Costanzo; G Piacentini; L Vicentini; F Armenante; P Mazzi; C Savio; L Faggioli; A Boner; M Palmieri
Journal:  Biochem Biophys Res Commun       Date:  1999-07-14       Impact factor: 3.575

2.  Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells.

Authors:  M K Majumdar; M A Thiede; J D Mosca; M Moorman; S L Gerson
Journal:  J Cell Physiol       Date:  1998-07       Impact factor: 6.384

3.  Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation.

Authors:  S P Bruder; N Jaiswal; S E Haynesworth
Journal:  J Cell Biochem       Date:  1997-02       Impact factor: 4.429

4.  Extended rituximab therapy in Waldenström's macroglobulinemia.

Authors:  S P Treon; C Emmanouilides; E Kimby; A Kelliher; F Preffer; A R Branagan; K C Anderson; S R Frankel
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

5.  Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line.

Authors:  M Faris; N Kokot; N Stahl; A E Nel
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

6.  Transcriptional regulation of the interleukin-6 gene in mesangial cells.

Authors:  C Grassl; B Luckow; D Schlöndorff; U Dendorfer
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

7.  Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway.

Authors:  Michelle B Miranda; Hong Xu; James A Torchia; Daniel E Johnson
Journal:  Leuk Res       Date:  2005-11       Impact factor: 3.156

8.  Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation.

Authors:  C Gerhartz; B Heesel; J Sasse; U Hemmann; C Landgraf; J Schneider-Mergener; F Horn; P C Heinrich; L Graeve
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

9.  Development and characterization of a human marrow stromal cell line that enhances osteoclast-like cell formation.

Authors:  S Takahashi; S V Reddy; M Dallas; R Devlin; J Y Chou; G D Roodman
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

10.  Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.

Authors:  Manik Chatterjee; Thorsten Stühmer; Pia Herrmann; Kurt Bommert; Bernd Dörken; Ralf C Bargou
Journal:  Blood       Date:  2004-08-05       Impact factor: 22.113

View more
  31 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.

Authors:  Josephine M Vos; Nickolas Tsakmaklis; Christopher J Patterson; Kirsten Meid; Jorge J Castillo; Philip Brodsky; Tomas Ganz; Steven T Pals; Marie José Kersten; Lian Xu; Guang Yang; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2017-08-10       Impact factor: 9.941

3.  Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.

Authors:  M Gupta; M Stenson; M O'Byrne; M J Maurer; T Habermann; J R Cerhan; G W Weiner; T E Witzig
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

4.  Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Authors:  Tomasz Sewastianik; Maria Luisa Guerrera; Keith Adler; Peter S Dennis; Kyle Wright; Vignesh Shanmugam; Ying Huang; Helen Tanton; Meng Jiang; Amanda Kofides; Maria G Demos; Audrey Dalgarno; Neil A Patel; Anwesha Nag; Geraldine S Pinkus; Guang Yang; Zachary R Hunter; Petr Jarolim; Nikhil C Munshi; Steven P Treon; Ruben D Carrasco
Journal:  Blood Adv       Date:  2019-11-12

5.  Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.

Authors:  Lucy S Hodge; Steven C Ziesmer; Zhi-Zhang Yang; Frank J Secreto; Anne J Novak; Stephen M Ansell
Journal:  Blood       Date:  2013-12-11       Impact factor: 22.113

Review 6.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

7.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

Review 8.  The bone marrow microenvironment in Waldenström macroglobulinemia.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-13

Review 9.  Novel treatment options for Waldenström macroglobulinemia.

Authors:  Houry Leblebjian; Amit Agarwal; Irene Ghobrial
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

10.  Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility.

Authors:  Yong Teng; Pushpankur Ghoshal; Lambert Ngoka; Yun Mei; John K Cowell
Journal:  Carcinogenesis       Date:  2013-05-14       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.